Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS

The prime purpose of this research currently being done was to set up an acceptable and high-operational ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method, which could simultaneously analyze the concentration levels of brexpiprazole, assisted medication for treatin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ying Zhang, Chenchen Wang, Xuegu Xu, Zhuofei Zhao, Xiao-hang Su, Huidan Zhu
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Brexpiprazole Rat Pharmacokinetics UPLC-MS/MS Plasma Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/f2ae2579474a4a1cadb26298625b4b4b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2ae2579474a4a1cadb26298625b4b4b
record_format	dspace
spelling	oai:doaj.org-article:f2ae2579474a4a1cadb26298625b4b4b2021-11-20T04:57:53ZDetermination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS1878-535210.1016/j.arabjc.2021.103430https://doaj.org/article/f2ae2579474a4a1cadb26298625b4b4b2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1878535221004457https://doaj.org/toc/1878-5352The prime purpose of this research currently being done was to set up an acceptable and high-operational ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method, which could simultaneously analyze the concentration levels of brexpiprazole, assisted medication for treating depression, and DM-3411, the principal metabolite of brexpiprazole in rats, and to examine the impact of baicalin on the metabolism of brexpiprazole in rats. After quick sample preparation using acetonitrile as a protein precipitating agent, the chromatograms of brexpiprazole, DM-3411 and aripiprazole (internal standard, IS) were successfully separated by Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column. The concentrations of the analytes were detected through a Xevo TQ-S triple quadrupole tandem by the positive ion scanning. The ranges of calibration curves for both brexpiprazole and DM-3411 were 0.5–100 ng/mL, and the approach represented fine linearity in the ranges. The lower limit of quantification (LLOQ) of brexpiprazole and DM-3411 could reach 0.5 ng/mL in the study. The range of intra-day and inter-day accuracy of the two analytes was between −10.6% and 12.3%, while the precision was ≤ 11.5%. The recovery rate of each compound was greater than 81.0%, and no obvious matrix effects were observable. In addition, the plasma sample quantitative detection of the compounds in the study remained stable under all conditions. Then, we used this assay to detect the plasma levels of brexpiprazole and DM-3411 from a herb-drug interaction investigation, in which 200 mg/kg baicalin remarkably increased the plasma concentration of brexpiprazole and changed brexpiprazole pharmacokinetics. This study will contribute to a better understanding of the pharmacokinetic properties of brexpiprazole when concurrent use with baicalin, and to an understanding of the unanticipated clinical risks.Ying ZhangChenchen WangXuegu XuZhuofei ZhaoXiao-hang SuHuidan ZhuElsevierarticleBrexpiprazoleRatPharmacokineticsUPLC-MS/MSPlasmaChemistryQD1-999ENArabian Journal of Chemistry, Vol 14, Iss 12, Pp 103430- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Brexpiprazole Rat Pharmacokinetics UPLC-MS/MS Plasma Chemistry QD1-999
spellingShingle	Brexpiprazole Rat Pharmacokinetics UPLC-MS/MS Plasma Chemistry QD1-999 Ying Zhang Chenchen Wang Xuegu Xu Zhuofei Zhao Xiao-hang Su Huidan Zhu Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
description	The prime purpose of this research currently being done was to set up an acceptable and high-operational ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method, which could simultaneously analyze the concentration levels of brexpiprazole, assisted medication for treating depression, and DM-3411, the principal metabolite of brexpiprazole in rats, and to examine the impact of baicalin on the metabolism of brexpiprazole in rats. After quick sample preparation using acetonitrile as a protein precipitating agent, the chromatograms of brexpiprazole, DM-3411 and aripiprazole (internal standard, IS) were successfully separated by Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column. The concentrations of the analytes were detected through a Xevo TQ-S triple quadrupole tandem by the positive ion scanning. The ranges of calibration curves for both brexpiprazole and DM-3411 were 0.5–100 ng/mL, and the approach represented fine linearity in the ranges. The lower limit of quantification (LLOQ) of brexpiprazole and DM-3411 could reach 0.5 ng/mL in the study. The range of intra-day and inter-day accuracy of the two analytes was between −10.6% and 12.3%, while the precision was ≤ 11.5%. The recovery rate of each compound was greater than 81.0%, and no obvious matrix effects were observable. In addition, the plasma sample quantitative detection of the compounds in the study remained stable under all conditions. Then, we used this assay to detect the plasma levels of brexpiprazole and DM-3411 from a herb-drug interaction investigation, in which 200 mg/kg baicalin remarkably increased the plasma concentration of brexpiprazole and changed brexpiprazole pharmacokinetics. This study will contribute to a better understanding of the pharmacokinetic properties of brexpiprazole when concurrent use with baicalin, and to an understanding of the unanticipated clinical risks.
format	article
author	Ying Zhang Chenchen Wang Xuegu Xu Zhuofei Zhao Xiao-hang Su Huidan Zhu
author_facet	Ying Zhang Chenchen Wang Xuegu Xu Zhuofei Zhao Xiao-hang Su Huidan Zhu
author_sort	Ying Zhang
title	Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
title_short	Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
title_full	Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
title_fullStr	Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
title_full_unstemmed	Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS
title_sort	determination and metabolism of brexpiprazole following baicalin to rats by a novel developed uplc-ms/ms
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/f2ae2579474a4a1cadb26298625b4b4b
work_keys_str_mv	AT yingzhang determinationandmetabolismofbrexpiprazolefollowingbaicalintoratsbyanoveldevelopeduplcmsms AT chenchenwang determinationandmetabolismofbrexpiprazolefollowingbaicalintoratsbyanoveldevelopeduplcmsms AT xueguxu determinationandmetabolismofbrexpiprazolefollowingbaicalintoratsbyanoveldevelopeduplcmsms AT zhuofeizhao determinationandmetabolismofbrexpiprazolefollowingbaicalintoratsbyanoveldevelopeduplcmsms AT xiaohangsu determinationandmetabolismofbrexpiprazolefollowingbaicalintoratsbyanoveldevelopeduplcmsms AT huidanzhu determinationandmetabolismofbrexpiprazolefollowingbaicalintoratsbyanoveldevelopeduplcmsms
_version_	1718419750722207744

Determination and metabolism of brexpiprazole following baicalin to rats by a novel developed UPLC-MS/MS

Ejemplares similares